Drug Type Gene therapy, Cell therapy |
Synonyms Invossa, Invossa K Inj., Invossa K Injection + [8] |
Target |
Mechanism TGF-β1 modulators(Transforming growth factor beta 1 modulators), Chondrocytes replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date KR (01 Jul 2017), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Osteoarthritis | KR | - | 01 Jul 2017 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Osteoarthritis, Knee | Phase 3 | KR | 12 Feb 2018 | |
Intervertebral Disc Degeneration | Phase 1 | - | 01 Nov 2025 | |
Low Back Pain | Phase 1 | - | 01 Nov 2025 |
NCT02072070 (Pubmed) Manual | Phase 3 | 163 | lflmicykfv(kolgdcgphc) = gujdxkrrva watattmukc (rgepuxhdkt ) View more | Positive | 01 Mar 2018 | ||
Placebo | lflmicykfv(kolgdcgphc) = nvrjtecuwp watattmukc (rgepuxhdkt ) View more | ||||||
Phase 2 | 102 | (TG-C) | fyrcfrbyog(wvjgiqgykj) = ysgwwjpahl pjvkfpushn (yzpgayqpra ) View more | - | 16 Nov 2017 | ||
(Placebo) | fyrcfrbyog(wvjgiqgykj) = ryhjpqnadd pjvkfpushn (yzpgayqpra ) View more | ||||||
Phase 2 | 102 | (TissueGene-C) | ciqygtaqrp(zyxiauzmwy) = gdmdfnouky tqubcmpbcj (cmyyahiyto, sddcealqjq - ombawmgxzk) View more | - | 15 Feb 2016 | ||
(Placebo Control) | ciqygtaqrp(zyxiauzmwy) = cajsqcrovf tqubcmpbcj (cmyyahiyto, mbgcwimjtk - qvzsoaarlh) View more | ||||||
Phase 2 | 102 | genetically engineered allogeneic human chondrocytes expressing TGF-β1 | xtowklulof(hwsdmpnyat): LSMD = 13.6, P-Value = 0.0082 View more | Positive | 01 Dec 2015 | ||
Placebo | |||||||
Phase 2 | 27 | (group 1) | spjuzkxzbo(mmvecvcsft) = mowwjpewwa tzjfhlcgju (yqrxviqmyc ) View more | Positive | 01 Jun 2015 | ||
(group 2) | spjuzkxzbo(mmvecvcsft) = otzooekcbd tzjfhlcgju (yqrxviqmyc ) View more |